By Sam Alfan.
Aesthetic Africa Limited has failed in its bid to block rival companies from distributing HydraFacial LLC products after the High Court vacated earlier orders that had temporarily barred the companies from doing so.
Justice Josephine Mongare dismissed Aesthetic Africa’s application seeking to restrain Dawa Life Sciences Limited and Skintech Pharma Limited from acting as the new distributors of HydraFacial LLC, using Aesthetic Africa’s client data, contacting its clients, or entering into any new distribution agreements.
In her ruling, Justice Mongare held that Aesthetic Africa had not established a prima facie case against Dawa Life Sciences or Skintech Pharma. She further noted that any loss the company might suffer is quantifiable and could be compensated through damages.
“I also agree that the balance of convenience weighs against granting the injunction,” the judge ruled.
“Skintech, as the appointed distributor, has demonstrated that it has already incurred significant costs, including placing a $29,290 order, hiring staff—as evidenced by pay slips—and is indeed suffering business disruption due to the interim orders previously issued by the court.”
The dispute arose after Aesthetic Africa filed an application seeking interim injunctions to stop Dawa Life Sciences and Skintech Pharma from acting as HydraFacial’s new distributors, using its client data, or entering into any new agreements pending the hearing and determination of the case.
Aesthetic Africa claimed that it had heavily invested in building the HydraFacial brand in Kenya through training, opening clinics, securing regulatory approvals, marketing, and hosting events. However, on January 23, 2025, HydraFacial, through its legal representatives, issued a 60-day notice terminating the agreement without offering any reasons.
The court heard that just 18 days later, on February 10, 2025—before the notice period had expired—HydraFacial appointed Skintech as its new distributor and allegedly began sharing Aesthetic Africa’s proprietary client data with the new entity.
Aesthetic Africa alleged that Sachi Mohindra, who had previously proposed a partnership in 2023 (which was rejected), orchestrated the move by maligning Aesthetic Africa to HydraFacial, ultimately securing the distributorship for herself and Skintech.l
The company further claimed that the two rival firms are unqualified, conducting unauthorized medical training without regulatory oversight, and putting public health at risk with unregulated procedures. Aesthetic Africa warned that, without injunctive relief, it would suffer significant financial loss, reputational damage, and that its clients would be exposed to potential harm.
In response, Dawa Life Sciences Managing Director Dr. Ajaykumar Shanabhal Patel emphasized that Dawa is a separate legal entity from Skintech and has no contractual relationship with either Aesthetic Africa or HydraFacial. He maintained that Dawa has never entered into any agreement to distribute HydraFacial products and argued that the orders sought were misplaced and did not affect its operations.
Skintech Pharma, through its director Reema Shah, pointed out a key technical flaw in Aesthetic Africa’s suit—specifically, that it was unclear whether the second defendant was meant to be Sachi Mohindra or Skintech, given they are distinct legal entities.
Skintech also told the court that Aesthetic Africa’s distribution agreement with HydraFacial was non-exclusive, contradicting the company’s claim that it held exclusive rights. This, they argued, amounted to material non-disclosure when Aesthetic Africa initially obtained the ex parte orders.
Skintech asserted that the termination of Aesthetic Africa’s distributorship was done via written notice, as per the terms of the contract. The company confirmed that it has since signed a valid Sales and Distribution Agreement with HydraFacial appointing it as the official distributor for East Africa.
The company further submitted that any financial loss suffered by Aesthetic Africa could be adequately addressed through damages. It emphasized that the interim orders had already caused business disruption and financial strain due to placed orders, hired staff, and halted operations.